Ipsen S.A. (IPN.PA)
| Previous Close | 114.40 |
| Open | 115.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 113.90 - 115.80 |
| 52 Week Range | 99.70 - 126.70 |
| Volume | |
| Avg. Volume | 64,332 |
| Market Cap | 9.529B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 14.40 |
| EPS (TTM) | 7.95 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 1.20 (1.05%) |
| Ex-Dividend Date | May 30, 2024 |
| 1y Target Est | 126.40 |
GlobeNewswireIpsen receives its second Shingo Prize for operational excellence
Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patientsIpsen’s first Shingo Prize was received by its production site in Signes, France in 2020, followed by the site in Dublin, Ireland todayThe Shingo Prize represents the highest standard of operational excellence in the world PARIS, FRANCE, 14 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has received the Shingo Prize for
GuruFocus.comIpsen SA (IPSEF) (H1 2024) Earnings Call Highlights: Strong Sales Growth Amidst Challenges
Ipsen SA (IPSEF) reports a robust 9.5% sales increase, while navigating Somatuline sales decline and rising R&D costs.
- GlobeNewswire
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)30 September 202483,814,526Gross total* of voting rights: 132,140,937Net total**
